Cita APA

Kishnani, P. S., Byrne, B. J., Claeys, K. G., Diaz-Manera, J., Dimachkie, M. M., Kushlaf, H., . . . Sebok, A. (2024). Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease.

Citación estilo Chicago

Kishnani, Priya S., et al. Switching Treatment to Cipaglucosidase Alfa Plus Miglustat Positively Affects Patient-reported Outcome Measures in Patients With Late-onset Pompe Disease. 2024.

Cita MLA

Kishnani, Priya S., et al. Switching Treatment to Cipaglucosidase Alfa Plus Miglustat Positively Affects Patient-reported Outcome Measures in Patients With Late-onset Pompe Disease. 2024.